Voyager Therapeutics(VYGR) - 2024 Q1 - Quarterly Results

EXHIBIT 99.1 Voyager Therapeutics Reports First Quarter 2024 Financial and Operating Results – Company announces clearance of IND application with FDA for anti-tau antibody VY-TAU01 for the treatment of Alzheimer's disease; expect to begin single ascending dose trial in the coming weeks – – Development candidates selected for Neurocrine-partnered GBA1 and Friedreich's Ataxia gene therapy programs; potential for three gene therapies, including SOD1- ALS, to enter the clinic in 2025 – – Appointed neurology cl ...